Joshua Romain
Hematology & Oncology · Travis Afb, CANPI 1528447448
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,816 of the $2,066 with a category attached, or 87.9%. 24 manufacturers reported payments, led by AstraZeneca at 29.5% of the total. Reporting peaked in 2023 at $861 and has fallen 96.9% since, to $27 in 2025. That places this record below the midpoint for hematology & oncology clinicians in CA, where the typical reported total is $3,371.
Across 85 payments — averaging $24.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$610
- E.r. Squibb & Sons, L.L.C.$268
- Merck$245
- Bristol Myers Squibb$124
- Daiichi Sankyo Inc.$121
- Takeda Pharmaceuticals U.S.A., Inc.$85
- plus $613 from 18 others
What the payments were for
- Speaking & faculty fees$25012%
- Food & beverage$1,81688%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 21 | $610 |
| E.r. Squibb & Sons, L.L.C. | 8 | $268 |
| Merck | 11 | $245 |
| Bristol Myers Squibb | 6 | $124 |
| Daiichi Sankyo Inc. | 5 | $121 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $85 |
| Sanofi | 3 | $72 |
| Exelixis Inc. | 2 | $67 |
| Taiho Oncology, Inc. | 3 | $65 |
| Pfizer | 2 | $49 |
| Boehringer Ingelheim | 2 | $49 |
| Mirati Therapeutics, Inc. | 2 | $46 |
| Incyte Corporation | 3 | $41 |
| Deciphera Pharmaceuticals Inc. | 2 | $31 |
| Amgen | 2 | $31 |
| Novartis | 1 | $25 |
| Astellas Pharma US Inc | 1 | $24 |
| Sumitomo Pharma America, Inc. | 1 | $19 |
| Boston Scientific | 1 | $19 |
| Clovis Oncology, Inc. | 1 | $18 |
| Ipsen Biopharmaceuticals, Inc | 1 | $15 |
| Polynovo North America LLC | 1 | $15 |
| Seagen Inc. | 1 | $14 |
| Genmab U.S., Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EMPLICITI$117
How this compares
$2,066 in reported general payments places this provider in the 40th percentile of 1,363 hematology & oncology providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Abiraterone Acetate | 18 | $3,320 |
| Prochlorperazine Maleate | 23 | $338 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Travis Afb
- Dennis SlamonLos Angeles$3.1M
- Sandra HorningStanford$2.5M
- Mohammadbagher ZiariCorona$2.5M
- George YaghmourLos Angeles$1.9M
- Robert VescioWest Hollywood$1.1M
- Kevin KellyLos Angeles$894K
- Johnny ChangEncino$884K
- Nitin RohatgiSacramento$814K
- Omid HamidSanta Monica$809K
- Catherine CoombsOrange$786K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.